Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: AVITA soars on FDA green light for RECELL GO System
Health & Biotech
‘Outstanding milestone’: FDA grants PharmAust orphan drug designation for monepantel
News
Closing Bell: Market mood swings as ASX tumbles, iron ore and lithium miners rise on China hopes
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
PharmAust plans for pivotal Phase 2/3 trial after key quarter of milestones
Health & Biotech
PharmAust bolsters manufacturing leadership to expand path to commercialisation
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 1
Health & Biotech
PharmAust inks approval from Macquarie University for Open-Label MND extension study
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 3
Health & Biotech
PharmAust files groundbreaking MND/ALS clinical data with the FDA
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results
Health & Biotech
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
News
ASX February winners: The best 50 stocks as a ‘super-heroic small cap’ soars 322%
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Health & Biotech
